Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) provided a corporate and operational update highlighting positive six-month clinical results from its First-in-Human (FIH) study, which support advancement to Group Two clinical surgeries. The company also launched a financing initiative to fund completion of the FIH study and accelerate commercialization activities.
Key highlights include the completion of a next-generation accommodating intraocular lens (Ocumetics Lens) with breakthrough technology, incorporating significant advancements in manufacturability, surgical performance and scalability. Manufacturing of the redesigned lens has commenced in Germany in preparation for planned Group Two surgeries, which remain on track for Q3 2026 in Mexico City. All regulatory requirements necessary to proceed to Group Two surgeries have been successfully completed. Additionally, strategic discussions continue with four of the world's seven largest ophthalmic companies regarding future partnership and commercialization opportunities.
Since reporting encouraging initial FIH clinical results, the company has executed multiple strategic initiatives. Positive six-month clinical data have supported progression to Group Two surgeries. Manufacturing of the redesigned Ocumetics Lens has commenced, regulatory milestones have been achieved, and strategic engagement with leading global ophthalmic companies continues to build momentum.
"The past several months have marked one of the most productive periods in Ocumetics' history," commented Dean Burns, President and Chief Executive Officer. "With group two surgeries expected to commence during the third quarter of 2026, we believe the Company is entering an important value-creation phase as we continue to build long-term shareholder value."
To support completion of its FIH clinical study and prepare for subsequent regulatory submissions, the company launched a financing initiative intended to fund the next phase of clinical development while supporting manufacturing, regulatory and commercialization activities. Proceeds are expected to be used to complete Group Two FIH surgeries in Mexico City, finalize manufacturing and quality verification of clinical lenses, complete sterilization and packaging activities, advance regulatory and quality assurance programs, and continue strategic partnership and commercialization initiatives.
During recent investor conferences, Ocumetics conducted more than 50 one-on-one meetings with institutional investors, family offices, high-net-worth investors, investment bankers/advisors and strategic industry participants. Management believes the continued level of investor engagement reflects growing recognition of the company's clinical progress and long-term commercial opportunity.
The company continues to engage with several of the world's leading ophthalmic organizations regarding potential strategic partnerships and commercialization opportunities. To date, management has met with representatives from four of the world's seven largest ophthalmic companies. Based on encouraging feedback, several organizations have expressed interest in reviewing additional clinical data following completion of Group Two surgeries. Follow-up discussions are tentatively scheduled for early Q4 2026 following the availability of Group Two one-month patient results.
Six-month follow-up data from Group One patients continue to demonstrate encouraging safety and performance outcomes. The surgical team reported successful implantation procedures and favorable post-operative outcomes. The study continues to achieve its primary objectives related to safety, lens delivery and distance vision correction. Anecdotally, patients have reported meaningful improvements in vision and quality of life, including one individual previously considered legally blind who is now qualified to drive.
Ocumetics has completed development of its next-generation solid-state accommodating intraocular lens, representing years of research, engineering and product refinement. The redesigned lens incorporates significant advancements intended to improve manufacturability, surgical handling, long-term reliability and accommodative performance while simplifying future commercial production. Expected benefits include enhanced accommodative performance, simplified lens architecture with one-piece design, improved manufacturing consistency, elimination of internal interface materials, optimized surgical implantation characteristics, improved compatibility with the redesigned lens delivery system, and greater scalability for commercial manufacturing.
Manufacturing of the redesigned Ocumetics Lens has commenced with the company's German manufacturing partner, Amiplant GmbH. Upcoming activities include finalization of manufacturing, product verification, sterilization, product packaging and release of clinical inventory ahead of the planned Q3 2026 clinical surgeries. Ocumetics has successfully completed all regulatory requirements necessary to proceed to Group Two patient enrollment.
Group Two FIH surgeries remain on schedule for Q3 2026 in Mexico City under the leadership of Principal Investigator Dr. Raphael Vasquez. Group Two patients are expected to receive the redesigned Ocumetics Lens delivered with the company's updated lens delivery system. Management believes positive one-month results of the Group Two patients will represent another meaningful value-creation milestone as the company advances toward larger clinical studies, future regulatory submissions and eventual commercialization.
With positive six-month clinical data, completion of the next-generation lens design, manufacturing underway, regulatory milestones achieved and strategic commercialization discussions continuing with leading global ophthalmic companies, Ocumetics believes it is well positioned to execute the next phase of its clinical development strategy.
